Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: Adenomas of the pituitary gland are among the most common types of tumors of the adult brain. Although adenomas are histologically benign, they may be associated with significant morbidity and mortality, mostly because of their invasive growth pattern and hormone hypersecretion. Current medical therapies are suppressive, acting at a receptor level. Thus, there is a need to identify novel cellular and molecular targets for pituitary tumors. We investigated the possible role of the NFκB transcription factor in pituitary tumor cell growth. METHODS: The effect of NFκB pathway inhibition on cellular viability was studied in the GH3 pituitary adenoma cell line, a well-characterized rat cell line that secretes growth hormone and prolactin. Cells were treated with mechanistically diverse pharmacological NFκB pathway inhibitors or with molecular inhibitors that were overexpressed in tumor cells before the assessment of cellular viability. NFκB activity was also assessed in GH3 cells using deoxyribonucleic acid binding assays. RESULTS: GH3 cells exhibited constitutive NFκB activity, which contributed to increased cellular proliferation. Treatment with wedelolactone, an IκB kinase inhibitor, or overexpression of an IκB super-repressor reduced cell viability, further implicating NFκB in pituitary tumor cell growth. Pharmacological or molecular inhibition of Akt similarly reduced GH3 viability and NFκB binding, suggesting that constitutive activation of NFκB may be, at least in part, mediated by Akt. CONCLUSION: Directed targeting of the Akt and NFκB signaling pathways may be a useful adjunct in the clinical management of pituitary tumors. Further elucidation of this pathway may yield novel information regarding the behavior of pituitary tumors in humans.

Original languageEnglish (US)
Pages (from-to)1122-1127
Number of pages6
JournalNeurosurgery
Volume62
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Pituitary Neoplasms
Adenoma
Growth Hormone
Pharmacology
Cell Line
Pituitary Gland
Growth
Brain Neoplasms
Prolactin
Cell Survival
Transcription Factors
Phosphotransferases
Cell Proliferation
Morbidity
Mortality
DNA
Neoplasms

Keywords

  • Adenoma
  • Akt
  • IκB
  • IκB kinase
  • NFκB
  • Pituitary
  • Proliferation

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells. / Vender, John R; Laird, Melissa D.; Dhandapani, Krishnan Michael.

In: Neurosurgery, Vol. 62, No. 5, 01.05.2008, p. 1122-1127.

Research output: Contribution to journalArticle

@article{a1d460d67e2a442a92669c3dad94ff1c,
title = "Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells",
abstract = "Objective: Adenomas of the pituitary gland are among the most common types of tumors of the adult brain. Although adenomas are histologically benign, they may be associated with significant morbidity and mortality, mostly because of their invasive growth pattern and hormone hypersecretion. Current medical therapies are suppressive, acting at a receptor level. Thus, there is a need to identify novel cellular and molecular targets for pituitary tumors. We investigated the possible role of the NFκB transcription factor in pituitary tumor cell growth. METHODS: The effect of NFκB pathway inhibition on cellular viability was studied in the GH3 pituitary adenoma cell line, a well-characterized rat cell line that secretes growth hormone and prolactin. Cells were treated with mechanistically diverse pharmacological NFκB pathway inhibitors or with molecular inhibitors that were overexpressed in tumor cells before the assessment of cellular viability. NFκB activity was also assessed in GH3 cells using deoxyribonucleic acid binding assays. RESULTS: GH3 cells exhibited constitutive NFκB activity, which contributed to increased cellular proliferation. Treatment with wedelolactone, an IκB kinase inhibitor, or overexpression of an IκB super-repressor reduced cell viability, further implicating NFκB in pituitary tumor cell growth. Pharmacological or molecular inhibition of Akt similarly reduced GH3 viability and NFκB binding, suggesting that constitutive activation of NFκB may be, at least in part, mediated by Akt. CONCLUSION: Directed targeting of the Akt and NFκB signaling pathways may be a useful adjunct in the clinical management of pituitary tumors. Further elucidation of this pathway may yield novel information regarding the behavior of pituitary tumors in humans.",
keywords = "Adenoma, Akt, IκB, IκB kinase, NFκB, Pituitary, Proliferation",
author = "Vender, {John R} and Laird, {Melissa D.} and Dhandapani, {Krishnan Michael}",
year = "2008",
month = "5",
day = "1",
doi = "10.1227/01.neu.0000325874.82999.75",
language = "English (US)",
volume = "62",
pages = "1122--1127",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Inhibition of nfκb reduces cellular viability in gh3 pituitary adenoma cells

AU - Vender, John R

AU - Laird, Melissa D.

AU - Dhandapani, Krishnan Michael

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Objective: Adenomas of the pituitary gland are among the most common types of tumors of the adult brain. Although adenomas are histologically benign, they may be associated with significant morbidity and mortality, mostly because of their invasive growth pattern and hormone hypersecretion. Current medical therapies are suppressive, acting at a receptor level. Thus, there is a need to identify novel cellular and molecular targets for pituitary tumors. We investigated the possible role of the NFκB transcription factor in pituitary tumor cell growth. METHODS: The effect of NFκB pathway inhibition on cellular viability was studied in the GH3 pituitary adenoma cell line, a well-characterized rat cell line that secretes growth hormone and prolactin. Cells were treated with mechanistically diverse pharmacological NFκB pathway inhibitors or with molecular inhibitors that were overexpressed in tumor cells before the assessment of cellular viability. NFκB activity was also assessed in GH3 cells using deoxyribonucleic acid binding assays. RESULTS: GH3 cells exhibited constitutive NFκB activity, which contributed to increased cellular proliferation. Treatment with wedelolactone, an IκB kinase inhibitor, or overexpression of an IκB super-repressor reduced cell viability, further implicating NFκB in pituitary tumor cell growth. Pharmacological or molecular inhibition of Akt similarly reduced GH3 viability and NFκB binding, suggesting that constitutive activation of NFκB may be, at least in part, mediated by Akt. CONCLUSION: Directed targeting of the Akt and NFκB signaling pathways may be a useful adjunct in the clinical management of pituitary tumors. Further elucidation of this pathway may yield novel information regarding the behavior of pituitary tumors in humans.

AB - Objective: Adenomas of the pituitary gland are among the most common types of tumors of the adult brain. Although adenomas are histologically benign, they may be associated with significant morbidity and mortality, mostly because of their invasive growth pattern and hormone hypersecretion. Current medical therapies are suppressive, acting at a receptor level. Thus, there is a need to identify novel cellular and molecular targets for pituitary tumors. We investigated the possible role of the NFκB transcription factor in pituitary tumor cell growth. METHODS: The effect of NFκB pathway inhibition on cellular viability was studied in the GH3 pituitary adenoma cell line, a well-characterized rat cell line that secretes growth hormone and prolactin. Cells were treated with mechanistically diverse pharmacological NFκB pathway inhibitors or with molecular inhibitors that were overexpressed in tumor cells before the assessment of cellular viability. NFκB activity was also assessed in GH3 cells using deoxyribonucleic acid binding assays. RESULTS: GH3 cells exhibited constitutive NFκB activity, which contributed to increased cellular proliferation. Treatment with wedelolactone, an IκB kinase inhibitor, or overexpression of an IκB super-repressor reduced cell viability, further implicating NFκB in pituitary tumor cell growth. Pharmacological or molecular inhibition of Akt similarly reduced GH3 viability and NFκB binding, suggesting that constitutive activation of NFκB may be, at least in part, mediated by Akt. CONCLUSION: Directed targeting of the Akt and NFκB signaling pathways may be a useful adjunct in the clinical management of pituitary tumors. Further elucidation of this pathway may yield novel information regarding the behavior of pituitary tumors in humans.

KW - Adenoma

KW - Akt

KW - IκB

KW - IκB kinase

KW - NFκB

KW - Pituitary

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=49049121113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49049121113&partnerID=8YFLogxK

U2 - 10.1227/01.neu.0000325874.82999.75

DO - 10.1227/01.neu.0000325874.82999.75

M3 - Article

C2 - 18580810

AN - SCOPUS:49049121113

VL - 62

SP - 1122

EP - 1127

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -